99mTc Tetrofosmin Uptake in Lung Cancer

1996 ◽  
Vol 37 (3P2) ◽  
pp. 763-766 ◽  
Author(s):  
M. Ishibashi ◽  
A. Hayashi ◽  
S. Takamori ◽  
H. Ohzono ◽  
S. Morita ◽  
...  
Keyword(s):  
Lung Tumor ◽  
Single Photon ◽  
Photon Emission ◽  
Myocardial Imaging ◽  
Single Photon Emission ◽  
Focal Uptake ◽  
99Mtc Tetrofosmin ◽  
Single Photon Emission Ct ◽  
Inferior Segment ◽  
The Right

This case report describes a 71-year-old man with a lung tumor in the posterior inferior segment of the right lung, detected on a screening chest radiograph. The patient underwent myocardial imaging with 99mTc tetrofosmin and 201Tl, using single photon emission CT (SPECT), and the tumor showed intense focal uptake of the radiotracer. This observation supports the recent suggestion that 99mTc tetrofosmin may be useful for oncologic imaging of lung carcinoma, and further studies may be warranted.

New Cardiac Cameras: Single-Photon Emission CT and PET

2014 ◽  
Vol 44 (4) ◽  
pp. 232-251 ◽  
Author(s):  
Piotr J. Slomka ◽  
Daniel S. Berman ◽  
Guido Germano
Keyword(s):  
Single Photon ◽  
Photon Emission ◽  
Single Photon Emission ◽  
Single Photon Emission Ct

scholarly journals Diagnostic Accuracy of Single Photon Emission CT in Alzheimer-Type Dementia.

1992 ◽  
Vol 29 (6) ◽  
pp. 463-468 ◽  
Author(s):  
Haruo Hanyu ◽  
Shinei Abe ◽  
Hisayuki Arai ◽  
Tetsuichi Asano ◽  
Toshihiko Iwamoto ◽  
...  
Keyword(s):  
Diagnostic Accuracy ◽  
Single Photon ◽  
Photon Emission ◽  
Alzheimer Type ◽  
Single Photon Emission ◽  
Alzheimer Type Dementia ◽  
Single Photon Emission Ct

scholarly journals Limited value of99mTc depreotide single photon emission CT compared with CT for the evaluation of pulmonary lesions

2012 ◽  
Vol 85 (1015) ◽  
pp. e307-e313 ◽  
Author(s):  
S W Harders ◽  
H H Madsen ◽  
K Hjorthaug ◽  
M Rehling ◽  
T R Rasmussen ◽  
...  
Keyword(s):  
Single Photon ◽  
Photon Emission ◽  
Single Photon Emission ◽  
Pulmonary Lesions ◽  
Single Photon Emission Ct

Single-Photon Emission CT to Access Outcomes in Children with Moyamoya Syndrome and Sickle Cell Disease Before and After Encephaloduroarteriosynagiosis

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2143-2143
Author(s):  
Sharada A. Sarnaik ◽  
Moira M. Lancelot
Keyword(s):  
Cerebral Perfusion ◽  
Pediatric Patients ◽  
Single Photon ◽  
Photon Emission ◽  
Moyamoya Syndrome ◽  
Cell Disease ◽  
Single Photon Emission ◽  
Vascular Reserve ◽  
Single Photon Emission Ct ◽  
Before And After

Abstract Abstract 2143 Background: About 11% of patients with sickle cell disease (SCD) will develop and ischemic stroke by 20 years. Patients with SCD and Moyamoya Syndrome (MMS) are at an especially high risk for developing stroke. Encephaloduroarteriosynagiosis (EDAS) is emerging as a safe and effective method for the treatment of MMS in Pediatric patients with SCD since it provides improved revascularization. Single-photon emission CT (SPECT) has been used in pediatric MMS patients to demonstrate regions of decreased cerebral perfusion and cerebrovascular reserve. The use of SPECT in SCD patients with MMS undergoing EDAS has not been evaluated. Methods: Between 2001 and 2011 we had 45 patients with SCD who developed clinical evidence of cerebrovascular accident (CVA), transient ischemic attack (TIA), or seizure with radiologic evidence (magnetic resonance and or angiography) of MMS. 20 underwent surgical revascularization with EDAS. Vascular reserve and cerebral perfusion was assessed with SPECT before and after EDAS in 9 patients. Results: 6/9 patients had bilateral EDAS while 3/9 had unilateral EDAS. The postoperative clinical outcome of each patient was assigned to one of the following 3 categories based on the SPECT reports: (1) improved if there was increased perfusion and vascular reserve after EDAS, (2) stable if there were no new areas of decreased perfusion or vascular reserve after EDAS and (3) worsened if there were new areas of decreased perfusion or vascular reserve with increased risk for future infarct after EDAS. 6/9 patients showed improvement, 2/9 patients showed stable cerebral perfusion and vascular reserve and 1 patient showed additional areas at risk for future infarct. SPECT was performed on average 5.7 (range 1.5–16.1) months before EDAS and 16.2 (range 1–47.1) months after EDAS. Conclusions: SPECT performed before and after EDAS of the involved cerebral hemispheres can assess effectiveness of revascularization surgery and may predict the further clinical outcomes of pediatric patients with SCD and MMS. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document